VXRT Quote, Financials, Valuation and Earnings

Inovio Pharmaceuticals has a net margin of -74.68% compared to Vaxart's net margin of -30140.49%. Vaxart's return on equity of -94.14% beat Inovio Pharmaceuticals's return on equity of -125.47%.

Vaxart has a consensus price target of $4.67, signalling upside risk potential of 1052.55%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.50 which suggests that it could grow by 447.45%. Given that Vaxart has higher upside potential than Inovio Pharmaceuticals, analysts believe Vaxart is more attractive than Inovio Pharmaceuticals.

Vaxart has a beta of 1.144, which suggesting that the stock is 14.422% more volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.307, suggesting its more volatile than the S&P 500 by 30.734%.

Vaxart has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxart pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Vaxart quarterly revenues are $20.9M, which are larger than Inovio Pharmaceuticals quarterly revenues of $65.3K. Vaxart's net income of -$15.6M is higher than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Vaxart's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxart is 1.85x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Lexicon Pharmaceuticals has a net margin of -74.68% compared to Vaxart's net margin of -2004.36%. Vaxart's return on equity of -94.14% beat Lexicon Pharmaceuticals's return on equity of -90.8%.

Vaxart has a consensus price target of $4.67, signalling upside risk potential of 1052.55%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $2.58 which suggests that it could grow by 91.11%. Given that Vaxart has higher upside potential than Lexicon Pharmaceuticals, analysts believe Vaxart is more attractive than Lexicon Pharmaceuticals.

Vaxart has a beta of 1.144, which suggesting that the stock is 14.422% more volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.928%.

Vaxart has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxart pays -- of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

Vaxart quarterly revenues are $20.9M, which are larger than Lexicon Pharmaceuticals quarterly revenues of $1.3M. Vaxart's net income of -$15.6M is higher than Lexicon Pharmaceuticals's net income of -$25.3M. Notably, Vaxart's price-to-earnings ratio is -- while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxart is 1.85x versus 15.10x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of -74.68% compared to Vaxart's net margin of 82.81%. Vaxart's return on equity of -94.14% beat Novavax's return on equity of --.

Vaxart has a consensus price target of $4.67, signalling upside risk potential of 1052.55%. On the other hand Novavax has an analysts' consensus of $13.43 which suggests that it could grow by 91.84%. Given that Vaxart has higher upside potential than Novavax, analysts believe Vaxart is more attractive than Novavax.

Vaxart has a beta of 1.144, which suggesting that the stock is 14.422% more volatile than S&P 500. In comparison Novavax has a beta of 2.691, suggesting its more volatile than the S&P 500 by 169.079%.

Vaxart has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxart pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

Vaxart quarterly revenues are $20.9M, which are smaller than Novavax quarterly revenues of $626.3M. Vaxart's net income of -$15.6M is lower than Novavax's net income of $518.6M. Notably, Vaxart's price-to-earnings ratio is -- while Novavax's PE ratio is 2.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxart is 1.85x versus 0.96x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics has a net margin of -74.68% compared to Vaxart's net margin of -475.33%. Vaxart's return on equity of -94.14% beat Sangamo Therapeutics's return on equity of -269.87%.

Vaxart has a consensus price target of $4.67, signalling upside risk potential of 1052.55%. On the other hand Sangamo Therapeutics has an analysts' consensus of $4.10 which suggests that it could grow by 749.04%. Given that Vaxart has higher upside potential than Sangamo Therapeutics, analysts believe Vaxart is more attractive than Sangamo Therapeutics.

Vaxart has a beta of 1.144, which suggesting that the stock is 14.422% more volatile than S&P 500. In comparison Sangamo Therapeutics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.402%.

Vaxart has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxart pays -- of its earnings as a dividend. Sangamo Therapeutics pays out -- of its earnings as a dividend.

Vaxart quarterly revenues are $20.9M, which are larger than Sangamo Therapeutics quarterly revenues of $6.4M. Vaxart's net income of -$15.6M is higher than Sangamo Therapeutics's net income of -$30.6M. Notably, Vaxart's price-to-earnings ratio is -- while Sangamo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxart is 1.85x versus 1.61x for Sangamo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.